Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDUNA: Dual vs Triple Therapy in Naive HIV
NCT04295460Phase 4Unknown
- Sponsor
- Hospital Universitario Virgen del Rocío
- Start
- Mar 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dolutegravir and lamivudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Hospital Universitario Virgen del Rocío. Primary endpoint: Proviral HIV-DNA at 96 weeks. Status: unknown.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04295460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04295460.